Liver-targeting drugs and their effect on blood glucose and hepatic lipids

Younossi Z, Tacke F, Arrese M et al (2019) Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology 69(6):2672–2682. https://doi.org/10.1002/hep.30251 Younossi ZM, Golabi P, de Avila L et al (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 71(4):793–801. https://doi.org/10.1016/j.jhep.2019.06.021 Gastaldelli A, Cusi K (2019) From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep 1(4):312–328. https://doi.org/10.1016/j.jhepr.2019.07.002 Stefan N, Haring HU, Cusi K (2019) Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 7(4):313–324. https://doi.org/10.1016/S2213-8587(18)30154-2 Junker AE, Gluud LL, van Hall G, Holst JJ, Knop FK, Vilsboll T (2016) Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. J Hepatol 64(4):908–915. https://doi.org/10.1016/j.jhep.2015.11.014 Marra F, Svegliati-Baroni G (2018) Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 68(2):280–295. https://doi.org/10.1016/j.jhep.2017.11.014 Rosso C, Kazankov K, Younes R et al (2019) Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J Hepatol 71(5):1012–1021. https://doi.org/10.1016/j.jhep.2019.06.031 Gastaldelli A, Gaggini M, DeFronzo RA (2017) Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study. Diabetes 66(4):815–822. https://doi.org/10.2337/db16-1167 Madiraju AK, Erion DM, Rahimi Y et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510(7506):542–546. https://doi.org/10.1038/nature13270 European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59(6):1121–1140. https://doi.org/10.1007/s00125-016-3902-y Nascimbeni F, Aron-Wisnewsky J, Pais R et al (2016) Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol 3(1):e000075. https://doi.org/10.1136/bmjgast-2015-000075 Gastaldelli A, Miyazaki Y, Mahankali A et al (2006) The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 29(10):2275–2281. https://doi.org/10.2337/dc05-2445 Bril F, Kalavalapalli S, Clark VC et al (2018) Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clin Gastroenterol Hepatol 16(4):558–566 e552. https://doi.org/10.1016/j.cgh.2017.12.001 DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE (2019) Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res 16(2):133–143. https://doi.org/10.1177/1479164118825376 Harrison SA, Alkhouri N, Davison BA et al (2020) Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. J Hepatol 72(4):613–626. https://doi.org/10.1016/j.jhep.2019.10.023 Chen Z, Vigueira PA, Chambers KT et al (2012) Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor gamma-sparing thiazolidinedione. J Biol Chem 287(28):23537–23548. https://doi.org/10.1074/jbc.M112.363960 DePaoli AM, Higgins LS, Henry RR, Mantzoros C, Dunn FL, INT131-007 Study Group (2014) Can a selective PPARgamma modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care 37(7):1918–1923. https://doi.org/10.2337/dc13-2480 Acton JJ 3rd, Akiyama TE, Chang CH et al (2009) Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1 -yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume. J Med Chem 52(13):3846–3854. https://doi.org/10.1021/jm900097m Huan Y, Pan X, Peng J et al (2019) A novel specific peroxisome proliferator-activated receptor gamma (PPARgamma) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice. Diabetes Obes Metab 21(11):2553–2563. https://doi.org/10.1111/dom.13843 Belfort R, Berria R, Cornell J, Cusi K (2010) Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 95(2):829–836. https://doi.org/10.1210/jc.2009-1487 Yaghoubi M, Jafari S, Sajedi B et al (2017) Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 29(12):1385–1388. https://doi.org/10.1097/MEG.0000000000000981 Fernandez-Miranda C, Perez-Carreras M, Colina F, Lopez-Alonso G, Vargas C, Solis-Herruzo JA (2008) A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 40(3):200–205. https://doi.org/10.1016/j.dld.2007.10.002 Corpechot C, Chazouilleres O, Rousseau A et al (2018) A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med 378(23):2171–2181. https://doi.org/10.1056/NEJMoa1714519 Karhapaa P, Uusitupa M, Voutilainen E, Laakso M (1992) Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia. Clin Pharmacol Ther 52(6):620–626. https://doi.org/10.1038/clpt.1992.200 Day AP, Feher MD, Chopra R, Mayne PD (1993) The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism 42(7):839–842. https://doi.org/10.1016/0026-0495(93)90056-t Ida S, Kaneko R, Murata K (2019) Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis. Cardiovasc Diabetol 18(1):38. https://doi.org/10.1186/s12933-019-0845-x Krishnappa M, Patil K, Parmar K et al (2020) Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). Cardiovasc Diabetol 19(1):93. https://doi.org/10.1186/s12933-020-01073-w Zydus Cadila (2020) World’s first drug for the treatment of Non-Cirrhotic NASH. Press release March 5, 2020. Available from https://zyduscadila.com/public/pdf/pressrelease/Zydus_announces_world’s_first_drug_for_the_treatment_of_Non_Cirrhotic_NASH.pdf. Accessed 23 June 2020 Kaul U, Parmar D, Manjunath K et al (2019) New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc Diabetol 18(1):80. https://doi.org/10.1186/s12933-019-0884-3 Ratziu V, Harrison SA, Francque S et al (2016) Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology 150(5):1147–1159 e1145. https://doi.org/10.1053/j.gastro.2016.01.038 Boubia B, Poupardin O, Barth M et al (2018) Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) alpha/gamma/delta Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. J Med Chem 61(6):2246–2265. https://doi.org/10.1021/acs.jmedchem.7b01285 Inventiva (2020) Lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH). Press release June 15, 2020. Available from https://www.globenewswire.com/news-release/2020/06/15/2048284/0/en/Inventiva-s-lanifibranor-meets-the-primary-and-key-secondary-endpoints-in-the-Phase-IIb-NATIVE-clinical-trial-in-non-alcoholic-steatohepatitis-NASH.html. Accessed 23 June 2020 Genfit (2020) Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis. Press release May 11 2020. Available from https://ml-eu.globenewswire.com/Resource/Download/38e085e1-66f5-4251-8abe-648d0e7b9ed1. Accessed 23 June 2020 Mudaliar S, Henry RR, Sanyal AJ et al (2013) Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145(3):574–582 e571. https://doi.org/10.1053/j.gastro.2013.05.042 Younossi ZM, Ratziu V, Loomba R et al (2019) Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394(10215):2184–2196. https://doi.org/10.1016/S0140-6736(19)33041-7 Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385(9972):956–965. https://doi.org/10.1016/S0140-6736(14)61933-4 Pencek R, Marmon T, Roth JD, Liberman A, Hooshmand-Rad R, Young MA (2016) Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. Diabetes Obes Metab 18(9):936–940. https://doi.org/10.1111/dom.12681 Harrison SA, Rossi SJ, Paredes AH et al (2020) NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis. Hepatology 71(4):1198–1212. https://doi.org/10.1002/hep.30590 Harrison SA, Neff G, Guy CD et al (2021) Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. Gastroenterology 160(1):219–231 e211. https://doi.org/10.1053/j.gastro.2020.08.004 Rinella ME, Trotter JF, Abdelmalek MF et al (2019) Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol 70(4):735–744. https://doi.org/10.1016/j.jhep.2018.11.032 Tully DC, Rucker PV, Chianelli D et al (2017) Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). J Med Chem 60(24):9960–9973. https://doi.org/10.1021/acs.jmedchem.7b00907 Lucas KJ, Lopez P, Lawitz E et al (2020) Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results. Dig Liver Dis 52:e38. https://doi.org/10.1016/j.dld.2019.12.129 An P, Wei G, Huang P et al (2020) A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int 40(7):1655–1669. https://doi.org/10.1111/liv.14490 Chianelli D, Rucker PV, Roland J et al (2020) Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem 63(8):3868–3880. https://doi.org/10.1021/acs.jmedchem.9b01621 Burris TP, Solt LA, Wang Y et al (2013) Nuclear receptors and their selective pharmacologic modulators. Pharmacol Rev 65(2):710–778. https://doi.org/10.1124/pr.112.006833 Chen G, Liang G, Ou J, Goldstein JL, Brown MS (2004) Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A 101(31):11245–11250. https://doi.org/10.1073/pnas.0404297101 Beaven SW, Matveyenko A, Wroblewski K et al (2013) Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance. Cell Metab 18(1):106–117. https://doi.org/10.1016/j.cmet.2013.04.021 Dou F, Chen J, Cao H et al (2019) Anti-atherosclerotic effects of LXRalpha agonist through induced conversion of M1 macrophage to M2. Am J Transl Res 11(6):3825–3840 Griffett K, Welch RD, Flaveny CA, Kolar GR, Neuschwander-Tetri BA, Burris TP (2015) The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. Mol Metab 4(4):353–357. https://doi.org/10.1016/j.molmet.2015.01.009 Kirchgessner TG, Sleph P, Ostrowski J et al (2016) Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils. Cell Metab 24(2):223–233. https://doi.org/10.1016/j.cmet.2016.07.016 Nambi P, Basso MD, Chen L et al (2007) Abstract 1453: LXR-623, a novel Liver X Receptor modulator, displays neutral lipid effects in Cholesteryl Ester Transfer Protein-expressing species and inhibits atherosclerotic lesion progression in Low Density Lipoprotein receptor knockout mice. Circulation 116(suppl_16):II_299–II_299. https://doi.org/10.1161/circ.116.suppl_16.II_299-a Katz A, Udata C, Ott E et al (2009) Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol 49(6):643–649. https://doi.org/10.1177/0091270009335768 Grefhorst A, van Dijk TH, Hammer A et al (2005) Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab 289(5):E829–E838. https://doi.org/10.1152/ajpendo.00165.2005 Chisholm JW, Hong J, Mills SA, Lawn RM (2003) The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res 44(11):2039–2048. https://doi.org/10.1194/jlr.M300135-JLR200 Griffett K, Burris TP (2016) Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease. Biochem Biophys Res Commun 479(3):424–428. https://doi.org/10.1016/j.bbrc.2016.09.036 Liu Y, Yan C, Wang Y et al (2006) Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. Endocrinology 147(11):5061–5068. https://doi.org/10.1210/en.2006-0243 Dong Y, Gao G, Fan H, Li S, Li X, Liu W (2015) Activation of the Liver X Receptor by Agonist TO901317 Improves Hepatic Insulin Resistance via Suppressing Reactive Oxygen Species and JNK Pathway. PLoS One 10(4):e0124778. https://doi.org/10.1371/journal.pone.0124778 Schultz JR, Tu H, Luk A et al (2000) Role of LXRs in control of lipogenesis. Genes Dev 14(22):2831–2838. https://doi.org/10.1101/gad.850400 Cui J, Philo L, Nguyen P et al (2016) Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J Hepatol 65(2):369–376. https://doi.org/10.1016/j.jhep.2016.04.021 Watanabe T, Tamura Y, Kakehi S et al (2015) Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study. J Diabetes Investig 6(2):164–172. https://doi.org/10.1111/jdi.12262 Joy TR, McKenzie CA, Tirona RG et al (2017) Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol 23(1):141–150. https://doi.org/10.3748/wjg.v23.i1.141 Seko Y, Sumida Y, Tanaka S et al (2017) Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res 47(10):1072–1078. https://doi.org/10.1111/hepr.12834 Dong Y, Lv Q, Li S et al (2017) Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 41(3):284–295. https://doi.org/10.1016/j.clinre.2016.11.009 Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679–690. https://doi.org/10.1016/S0140-6736(15)00803-X Newsome PN, Buchholtz K, Cusi K et al (2020) A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. https://doi.org/10.1056/NEJMoa2028395 Bi Y, Zhang B, Xu W et al (2014) Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes. Acta Diabetol 51(5):865–873. https://doi.org/10.1007/s00592-014-0638-3 Gastaldelli A, Gaggini M, Daniele G et al (2016) Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Hepatology 64(6):2028–2037. https://doi.org/10.1002/hep.28827 Shao N, Kuang HY, Hao M, Gao XY, Lin WJ, Zou W (2014) Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev 30(6):521–529. https://doi.org/10.1002/dmrr.2561 Klonoff DC, Buse JB, Nielsen LL et al (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24(1):275–286. https://doi.org/10.1185/030079908x253870 Gastaldelli A, Repetto E, Guja C et al (2020) Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes Obes Metab 22(3):393–403. https://doi.org/10.1111/dom.13907 Liu L, Yan H, Xia M et al (2020) Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev 36(5):e3292. https://doi.org/10.1002/dmrr.3292 Gluud LL, Knop FK, Vilsboll T (2014) Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open 4(12):e005325. https://doi.org/10.1136/bmjopen-2014-005325 Cusi K, Sattar N, Garcia-Perez LE et al (2018) Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diabet Med 35(10):1434–1439. https://doi.org/10.1111/dme.13697 Seko Y, Sumida Y, Tanaka S et al (2017) Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res 47(11):1206–1211. https://doi.org/10.1111/hepr.12837 Kuchay MS, Krishan S, Mishra SK et al (2020) Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 63(11):2434–2445. https://doi.org/10.1007/s00125-020-05265-7 Armstrong MJ, Hull D, Guo K et al (2016) Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 64(2):399–408. https://doi.org/10.1016/j.jhep.2015.08.038 Newsome P, Francque S, Harrison S et al (2019) Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther 50(2):193–203. https://doi.org/10.1111/apt.15316 Seghieri M, Rebelos E, Gastaldelli A et al (2013) Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia 56(1):156–161. https://doi.org/10.1007/s00125-012-2738-3 Yan J, Yao B, Kuang H et al (2019) Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology 69(6):2414–2426. https://doi.org/10.1002/hep.30320 Tang A, Rabasa-Lhoret R, Castel H et al (2015) Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 38(7):1339–1346. https://doi.org/10.2337/dc14-2548 Matikainen N, Soderlund S, Bjornson E et al (2019) Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. Diabetes Obes Metab 21(1):84–94. https://doi.org/10.1111/dom.13487 Whyte MB, Shojaee-Moradie F, Sharaf SE et al (2019) Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance. J Clin Endocrinol Metab 104(2):359–368. https://doi.org/10.1210/jc.2018-01176 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al (2015) Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 149(2):367–378 e365; quiz e314-365. https://doi.org/10.1053/j.gastro.2015.04.005 Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392(10160):2180–2193. https://doi.org/10.1016/S0140-6736(18)32260-8 Hartman ML, Sanyal AJ, Loomba R et al (2020) Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes Care 43(6):1352–1355. https://doi.org/10.2337/dc19-1892 Frias JP, Nauck MA, Van J et al (2020) Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab 22(6):938–946. https://doi.org/10.1111/dom.13979 Brandt SJ, Gotz A, Tschop MH, Muller TD (2018) Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides 100:190–201. https://doi.org/10.1016/j.peptides.2017.12.021 Ambery P, Parker VE, Stumvoll M et al (2018) MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 391(10140):2607–2618. https://doi.org/10.1016/S0140-6736(18)30726-8 Skarbaliene J, Madsen AN, Mouritzen U, Bak HH, Just R (2017) Exploring the therapeutic potential of Glucagon/GLP-1 dual agonist ZP2929 in a mouse model of diet induced and biopsy-confirmed non-alcoholic steatohepatitis. J Hepatol 66(1):S102. https://doi.org/10.1016/s0168-8278(17)30466-x Choi J, Kim JK, Lee SM et al (2020) 1830-P: Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in CDHFD-Induced NASH and Fibrosis Mice. Diabetes 69(Supplement 1):1830. https://doi.org/10.2337/db20-1830-P Abdelmalek M, Choi J, Kim Y, Seo K, Hompesch M, Baek S (2020) HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial. J Hepatol 73:S124. https://doi.org/10.1016/S0168-8278(20)30765-0 Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G (2020) Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 111S:154170. https://doi.org/10.1016/j.metabol.2020.154170 Verma S, McMurray JJV (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 61(10):2108–2117. https://doi.org/10.1007/s00125-018-4670-7 Kahl S, Gancheva S, Strassburger K et al (2020) Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. Diabetes Care 43(2):298–305. https://doi.org/10.2337/dc19-0641 Kuchay MS, Krishan S, Mishra SK et al (2018) Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). Diabetes Care 41(8):1801–1808. https://doi.org/10.2337/dc18-0165 Eriksson JW, Lundkvist P, Jansson PA et al (2018) Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 61(9):1923–1934. https://doi.org/10.1007/s00125-018-4675-2 Cusi K, Bril F, Barb D et al (2019) Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab 21(4):812–821. https://doi.org/10.1111/dom.13584 Akuta N, Watanabe C, Kawamura Y et al (2017) Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies. Hepatol Commun 1(1):46–52. https://doi.org/10.1002/hep4.1019 Sumida Y, Murotani K, Saito M et al (2019) Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial). Hepatol Res 49(1):64–71. https://doi.org/10.1111/hepr.13236 Shibuya T, Fushimi N, Kawai M et al (2018) Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diabetes Obes Metab 20(2):438–442. https://doi.org/10.1111/dom.13061 Miyake T, Yoshida S, Furukawa S et al (2018) Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease. Open Med (Wars) 13:402–409. https://doi.org/10.1515/med-2018-0059 Komiya C, Tsuchiya K, Shiba K et al (2016) Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS One 11(3):e0151511. https://doi.org/10.1371/journal.pone.0151511 Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A (2020) Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther 11(8):1849–1860. https://doi.org/10.1007/s13300-020-00867-1 Taheri H, Malek M, Ismail-Beigi F et al (2020) Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Adv Ther 37(11):4697–4708. https://doi.org/10.1007/s12325-020-01498-5 Castellana M, Cignarelli A, Brescia F et al (2019) Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis. Sci Rep 9(1):19351. https://doi.org/10.1038/s41598-019-55524-w Cusi K, Sanyal AJ, Zhang S et al (2017) Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab 19(11):1630–1634. https://doi.org/10.1111/dom.12973 Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H (2007) Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 292(3):E829–E835. https://doi.org/10.1152/ajpendo.00133.2006 Cusi K, Sanyal AJ, Zhang S et al (2016) Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. Diabetes Obes Metab 18(Suppl 2):50–58. https://doi.org/10.1111/dom.12751 Anderwald C, Bernroider E, Krssak M et al (2002) Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 51(10):3025–3032. https://doi.org/10.2337/diabetes.51.10.3025 Stefan N, Haring HU (2013) The role of hepatokines in metabolism. Nat Rev Endocrinol 9(3):144–152. https://doi.org/10.1038/nrendo.2012.258 Zhang LY, Qu XN, Sun ZY, Zhang Y (2020) Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 44(5):674–680. https://doi.org/10.1016/j.clinre.2020.01.007 Esteghamati A, Afarideh M, Feyzi S, Noshad S, Nakhjavani M (2015) Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Diabetes Metab Syndr 9(4):258–265. https://doi.org/10.1016/j.dsx.2014.09.009 Lan T, Morgan DA, Rahmouni K et al (2017) FGF19, FGF21, and an FGFR1/beta-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia. Cell Metab 26(5):709–718 e703. https://doi.org/10.1016/j.cmet.2017.09.005 Charles ED, Neuschwander-Tetri BA, Pablo Frias J et al (2019) Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. Obesity (Silver Spring) 27(1):41–49. https://doi.org/10.1002/oby.22344 Sanyal A, Charles ED, Neuschwander-Tetri BA et al (2019) Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 392(10165):2705–2717. https://doi.org/10.1016/S0140-6736(18)31785-9 Rosenstock M, Ayalon M, Mansbach H, Liu Y, Margalit M (2019) LBP29 BIO89–100, a novel PEG-FGF21 analogue, is efficacious following weekly and every 2-week subcutaneous dosing in spontaneous diabetic cynomolgus monkeys. J Hepatol 70(LBP):e141–e382 Talukdar S, Zhou Y, Li D et al (2016) A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. Cell Metab 23(3):427–440. https://doi.org/10.1016/j.cmet.2016.02.001 Yin J, Bao L, Chen R, Gao W, Gao X, Yao W (2018) Enhanced expression and distinctive characterization of a long-acting FGF21 and its potential to alleviate nonalcoholic steatohepatitis. Biochimie 151:166–175. https://doi.org/10.1016/j.biochi.2018.05.020 Bao L, Yin J, Gao W, Wang Q, Yao W, Gao X (2018) A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway. Br J Pharmacol 175(16):3379–3393. https://doi.org/10.1111/bph.14383 Xu J, Lloyd DJ, Hale C et al (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58(1):250–259. https://doi.org/10.2337/db08-0392 Depaoli A, Phung VAN, Bashir MR et al (2019) 140-LB: NGM313, a Novel Activator of b-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects. Diabetes 68(Supplement 1):140-LB. https://doi.org/10.2337/db19-140-LB Barchetta I, Cimini FA, Chiappetta C et al (2020) Relationship between hepatic and systemic angiopoietin-like 3, hepatic vitamin D receptor expression and NAFLD in obesity. Liver Int 40(9):2139–2147. https://doi.org/10.1111/liv.14554 Ahmad Z, Banerjee P, Hamon S et al (2019) Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. Circulation 140(6):470–486. https://doi.org/10.1161/CIRCULATIONAHA.118.039107 Raal FJ, Rosenson RS, Reeskamp LF et al (2020) Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med 383(8):711–720. https://doi.org/10.1056/NEJMoa2004215 Dewey FE, Gusarova V, Dunbar RL et al (2017) Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med 377(3):211–221. https://doi.org/10.1056/NEJMoa1612790 Safadi R, Konikoff FM, Mahamid M et al (2014) The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12(12):2085–2091 e2081. https://doi.org/10.1016/j.cgh.2014.04.038 Ajmera VH, Cachay E, Ramers C et al (2019) MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial). Hepatology 70(5):1531–1545. https://doi.org/10.1002/hep.30674 Calle R, Bergman A, Somayaji V, Chidsey K, Kazierad D (2019) PS-110-Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with non-alcoholic fatty liver disease. J Hepatol 70(1, Supplement):e69–e70. https://doi.org/10.1016/S0618-8278(19)30122-7 Futatsugi K, Smith AC, Tu M et al (2020) Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose. J Med Chem 63(22):13546–13560. https://doi.org/10.1021/acs.jmedchem.0c00944 Syed-Abdul MM, Parks EJ, Gaballah AH et al (2020) Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology 72(1):103–118. https://doi.org/10.1002/hep.31000 Loomba R, Morgan E, Watts L et al (2020) Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 5(9):829–838. https://doi.org/10.1016/s2468-1253(20)30186-2 Okour M, Brigandi RA, Tenero D (2019) A population analysis of the DGAT1 inhibitor GSK3008356 and its effect on endogenous and meal-induced triglyceride turnover in healthy subjects. Fundam Clin Pharmacol 33(5):567–580. https://doi.org/10.1111/fcp.12455 Seo H, Choi SH, Kwak EY et al (2014) Determination of a novel diacylglycerol acyltransferase 1 inhibitor, 2-[4-(4-{5-[2-phenyl-5-(trifluoromethyl) oxazole-4-carboxamido]-1H-benzo[d]imidazol-2-yl} phenyl) cyclohexyl] acetic acid (KR-69232) in rat plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. Biomed Chromatogr 28(3):324–326. https://doi.org/10.1002/bmc.3053 Climax J, Newsome PN, Hamza M et al (2020) Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers. J Am Heart Assoc 9(16):e016334. https://doi.org/10.1161/JAHA.119.016334 Loomba R, Kayali Z, Noureddin M et al (2018) GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 155(5):1463–1473 e1466. https://doi.org/10.1053/j.gastro.2018.07.027 Lawitz EJ, Coste A, Poordad F et al (2018) Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 16(12):1983–1991 e1983. https://doi.org/10.1016/j.cgh.2018.04.042 Harrison SA, Bashir MR, Guy CD et al (2019) Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 394(10213):2012–2024. https://doi.org/10.1016/S0140-6736(19)32517-6 Luong XG, Stevens SK, Jekle A et al (2020) Regulation of gene transcription by thyroid hormone receptor beta agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). PLoS One 15(12):e0240338. https://doi.org/10.1371/journal.pone.0240338 Loomba R, Neutel J, Mohseni R et al (2019) LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial. Hepatol 70(1):e150–e151. https://doi.org/10.1016/s0618-8278(19)30266-x Feig PU, Shah S, Hermanowski-Vosatka A et al (2011) Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 13(6):498–504. https://doi.org/10.1111/j.1463-1326.2011.01375.x Rosenstock J, Banarer S, Fonseca VA et al (2010) The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33(7):1516–1522. https://doi.org/10.2337/dc09-2315 Hollis G, Huber R (2011) 11beta-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus. Diabetes Obes Metab 13(1):1–6. https://doi.org/10.1111/j.1463-1326.2010.01305.x Stefan N, Ramsauer M, Jordan P et al (2014) Inhibition of 11beta-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2(5):406–416. https://doi.org/10.1016/S2213-8587(13)70170-0 Heise T, Morrow L, Hompesch M et al (2014) Safety, efficacy and weight effect of two 11beta-HSD1 inhibitors in metformin-treated patients with type 2 diabetes. Diabetes Obes Metab 16(11):1070–1077. https://doi.org/10.1111/dom.12317 Bellaire S, Walzer M, Wang T, Krauwinkel W, Yuan N, Marek GJ (2019) Safety, Pharmacokinetics, and Pharmacodynamics of ASP3662, a Novel 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Healthy Young and Elderly Subjects. Clin Transl Sci 12(3):291–301. https://doi.org/10.1111/cts.12618 Markey KA, Ottridge R, Mitchell JL et al (2017) Assessing the Efficacy and Safety of an 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial. JMIR Res Protoc 6(9):e181. https://doi.org/10.2196/resprot.7806 Scott JS, Bowker SS, Deschoolmeester J et al (2012) Discovery of a potent, selective, and orally bioavailable acidic 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acet ic acid (AZD4017). J Med Chem 55(12):5951–5964. https://doi.org/10.1021/jm300592r Harno E, Cottrell EC, Yu A et al (2013) 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors still improve metabolic phenotype in male 11beta-HSD1 knockout mice suggesting off-target mechanisms. Endocrinology 154(12):4580–4593. https://doi.org/10.1210/en.2013-1613 Digenio A, Pham NC, Watts LM et al (2018) Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes. Diabetes Care 41(4):807–814. https://doi.org/10.2337/dc17-2132 Delibegovic M, Zimmer D, Kauffman C et al (2009) Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes 58(3):590–599. https://doi.org/10.2337/db08-0913 Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355(22):2297–2307. https://doi.org/10.1056/NEJMoa060326 Sanyal AJ, Chalasani N, Kowdley KV et al (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362(18):1675–1685. https://doi.org/10.1056/NEJMoa0907929 Cusi K, Orsak B, Bril F et al (2016) Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med 165(5):305–315. https://doi.org/10.7326/M15-1774 Ratziu V, Charlotte F, Bernhardt C et al (2010) Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51(2):445–453. https://doi.org/10.1002/hep.23270 Juurinen L, Kotronen A, Graner M, Yki-Jarvinen H (2008) Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J Clin Endocrinol Metab 93(1):118–124. https://doi.org/10.1210/jc.2007-1825 Lee YH, Kim JH, Kim SR et al (2017) Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness. J Korean Med Sci 32(1):60–69. https://doi.org/10.3346/jkms.2017.32.1.60 Colca JR, McDonald WG, Adams WJ (2018) MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis. Expert Opin Investig Drugs 27(7):631–636. https://doi.org/10.1080/13543784.2018.1494153 Roy S, Ghosh A (2019) Significant Reduction of Elevated Triglycerides and Liver Fibrosis in Diabetic Dyslipidemia with Saroglitazar: A Case Report. Cureus 11(12):e6361. https://doi.org/10.7759/cureus.6361 Stirban AO, Andjelkovic M, Heise T et al (2016) Aleglitazar, a dual peroxisome proliferator-activated receptor-alpha/gamma agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial. Diabetes Obes Metab 18(7):711–715. https://doi.org/10.1111/dom.12620 Fagerberg B, Edwards S, Halmos T et al (2005) Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48(9):1716–1725. https://doi.org/10.1007/s00125-005-1846-8 Coletta DK, Fernandez M, Cersosimo E, Gastaldelli A, Musi N, DeFronzo RA (2015) The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo. Diabet Med 32(5):657–664. https://doi.org/10.1111/dme.12664 Fernandez M, Gastaldelli A, Triplitt C et al (2011) Metabolic effects of muraglitazar in type 2 diabetic subjects. Diabetes Obes Metab 13(10):893–902. https://doi.org/10.1111/j.1463-1326.2011.01429.x Ding SY, Tigno XT, Braileanu GT, Ito K, Hansen BC (2007) A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys. Metabolism 56(10):1334–1339. https://doi.org/10.1016/j.metabol.2007.05.019 Doebber TW, Kelly LJ, Zhou G et al (2004) MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities. Biochem Biophys Res Commun 318(2):323–328. https://doi.org/10.1016/j.bbrc.2004.04.032 Trauner M, Gulamhusein A, Hameed B et al (2019) The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology 70(3):788–801. https://doi.org/10.1002/hep.30509 Patel K, Harrison SA, Elkhashab M et al (2020) Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology 72(1):58–71. https://doi.org/10.1002/hep.31205 Aspinall R, Shennak M, Stocia G et al (2020) Nidufexor, a non-bile acid FXR agonist, decreases ALT and hepatic fat fraction in patients with NASH after 12 weeks dosing. J Hepatol 73:S4-S5 Erstad DJ, Farrar CT, Ghoshal S et al (2018) Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist. Hepatol Commun 2(7):821–835. https://doi.org/10.1002/hep4.1193 Harrison SA, Rinella ME, Abdelmalek MF et al (2018) NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 391(10126):1174–1185. https://doi.org/10.1016/S0140-6736(18)30474-4 Hirschfield GM, Chazouilleres O, Drenth JP et al (2019) Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol 70(3):483–493. https://doi.org/10.1016/j.jhep.2018.10.035 DePaoli AM, Zhou M, Kaplan DD et al (2019) FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis. Diabetes 68(6):1315–1328. https://doi.org/10.2337/db18-1305 Frias JP, Bastyr EJ 3rd, Vignati L et al (2017) The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. Cell Metab 26(2):343–352 e342. https://doi.org/10.1016/j.cmet.2017.07.011 Nahra R, Gadde K, Hirshberg B et al (2020) AS076 - Effects of cotadutide on biomarkers of non-alcoholic steatohepatitis in overweight or obese subjects with type 2 diabetes mellitus: a 54-week analysis of a randomized phase 2b study. J Hepatol 73:S54–S55. https://doi.org/10.1016/S0168-8278(20)30655-3 Kim JK, Kim J, Lee SM, Lee J, Lee SH, Choi IY (2019) 991-P: Potential of a Novel Long-Acting Glucagon Analog, HM15136, for the Treatment of Obesity. Diabetes 68(Supplement 1):991. https://doi.org/10.2337/db19-991-P Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK (2020) Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. Dig Dis Sci 65(2):623–631. https://doi.org/10.1007/s10620-019-5477-1 Inoue M, Hayashi A, Taguchi T et al (2019) Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. J Diabetes Investig 10(4):1004–1011. https://doi.org/10.1111/jdi.12980 Itani T, Ishihara T (2018) Efficacy of canagliflozin against nonalcoholic fatty liver disease: A prospective cohort study. Obes Sci Pract 4(5):477–482. https://doi.org/10.1002/osp4.294 Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S (2016) Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 42(1):25–32. https://doi.org/10.1016/j.diabet.2015.10.003 Li B, Wang Y, Ye Z et al (2018) Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. J Pharm Pharm Sci 21(1):222–235. https://doi.org/10.18433/jpps29831 Seko Y, Nishikawa T, Umemura A et al (2018) Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. Diabetes Metab Syndr Obes 11:835–843. https://doi.org/10.2147/DMSO.S184767 Lee PCH, Gu Y, Yeung MY et al (2018) Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study. Diabetes Ther 9(1):285–295. https://doi.org/10.1007/s13300-017-0355-3 Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375(9733):2223–2233. https://doi.org/10.1016/S0140-6736(10)60407-2 Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y (2017) Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. Curr Ther Res Clin Exp 87:13–19. https://doi.org/10.1016/j.curtheres.2017.07.002 Liu J, Tarasenko L, Terra SG et al (2019) Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies. Diab Vasc Dis Res 16(5):415–423. https://doi.org/10.1177/1479164119842513 Han E, Lee YH, Lee BW, Kang ES, Cha BS (2020) Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. J Clin Med 9(1). https://doi.org/10.3390/jcm9010259 Ohki T, Isogawa A, Toda N, Tagawa K (2016) Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. Clin Drug Investig 36(4):313–319. https://doi.org/10.1007/s40261-016-0383-1 Ito D, Shimizu S, Inoue K et al (2017) Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. Diabetes Care 40(10):1364–1372. https://doi.org/10.2337/dc17-0518 Takase T, Nakamura A, Miyoshi H, Yamamoto C, Atsumi T (2017) Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. Endocr J 64(3):363–367. https://doi.org/10.1507/endocrj.EJ16-0295 Ohta A, Kato H, Ishii S et al (2017) Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes. Expert Opin Pharmacother 18(14):1433–1438. https://doi.org/10.1080/14656566.2017.1363888 Bando Y, Ogawa A, Ishikura K et al (2017) The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus. Diabetol Int 8(2):218–227. https://doi.org/10.1007/s13340-016-0302-y Ozaki A, Yoneda M, Kessoku T et al (2020) Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). Contemp Clin Trials Commun 17:100516. https://doi.org/10.1016/j.conctc.2019.100516 He YL, Haynes W, Meyers CD et al (2019) The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes. Diabetes Obes Metab 21(6):1311–1321. https://doi.org/10.1111/dom.13654 Yokote K, Sano M, Tsumiyama I, Keefe D (2020) Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity. Diabetes Obes Metab 22(7):1102–1110. https://doi.org/10.1111/dom.14006 Iruarrizaga-Lejarreta M, Varela-Rey M, Fernandez-Ramos D et al (2017) Role of Aramchol in steatohepatitis and fibrosis in mice. Hepatol Commun 1(9):911–927. https://doi.org/10.1002/hep4.1107 Nio Y, Hasegawa H, Okamura H, Miyayama Y, Akahori Y, Hijikata M (2016) Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment. Antivir Res 132:262–267. https://doi.org/10.1016/j.antiviral.2016.07.003